JO3270B1 - مشتقات كوينولين بصفة عوامل مضادة للبكتيريا - Google Patents
مشتقات كوينولين بصفة عوامل مضادة للبكتيرياInfo
- Publication number
- JO3270B1 JO3270B1 JOP/2006/0189A JOP20060189A JO3270B1 JO 3270 B1 JO3270 B1 JO 3270B1 JO P20060189 A JOP20060189 A JO P20060189A JO 3270 B1 JO3270 B1 JO 3270B1
- Authority
- JO
- Jordan
- Prior art keywords
- alkyl
- alky1
- hydrogen
- alkylthio
- halo
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 206010062207 Mycobacterial infection Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتعلق الاختراع الحالي باستخدام مركب (compound) لتصنيع دواء (medicament) لمعالجة عدوى بكتيرية (bacterial infection) بشرط ان تكون العدوى البكترية ( bacterial infection) خلاف العدوى البكتيرية الفطرية (Mycobacterial infection) ويكون المركب المذكور هو مركب من الصيغة ( Ia) او ( Ib) : ملح اضافي حمض او قاعدة (acid or base addition salt) مقبول دوائيا منه، شكل ايزومري فراغي كيماوئيا (stereochemically isomeric form) منه شكل توتومري (tautomeric form) منه او N اوكسيد ( N- oxide) منه ، حيث يكون R1 هو هيدروجين ( HYDROGEN) ، هالو ( halo) هالو الكيل ( haloalky1) ، سيانو (cyano) ، هيدروكسي (haloalky) Ar، Het، الكيل (alky1) الكيل اوكسي (alkyloxy) ، الكيل ثيو (alkylthio) ، الكيل اوكسي الكيل ( alkyloxyalky1) الكيل ثيو الكيل (alkyloxyalky1) ، Ar- الكيل ( Ar- alky1) او ثنائي (Ar) الكيل (di(Aralky1) ; p هو 1 الى 4 R2 هو هيدروجين (hydrogen) هيدروكسي (hydroxy) مركابتو (mercapto) الكيل اوكسي (alkyloxy) الكيل اوكسي اوكسي (alkyloxyalkyloxy) الكيل ثيو (alkylthio) احادي او ثنائي (الكيل ) امينو (mono or di(alky1 )amino) او حيث يكون Y هو CH2، O، S NH او N الكيل (N- alky1) R3 هو Ar او Het R5 R4 كل منهما على حدة يكون هيدروجين( hydrogen)، الكيل (alky1) او بنزيل (benzy1) او يؤخذ R4 و R5 معا مع ذرة N المرتبطة معهما؛ R6 هو هيدروجين (hydrogen) هالو (halo) هالو الكيل (haloalky1) هيدروكسي ( hydroxy) Ar ، الكيل (alky1) الكيل اوكسي (alkyloxy) الكيل ثيو (alkylthio) الكيل اوكسي الكيل (alkyloxyalky1) ، الكيل ثيو الكيل (alkylthioalky1) Ar -الكيل (Ar-alky1) او ثنائي (Ar) الكيل (di(Ar)alky1) او قد يؤخذ شقا R6 المتجاوران معا لتشكيل CH=CH-CH=CH- -؛ r هو 1 الى 5؛ R7 هو هيدروجين (HYDROGEN) الكيل (alky1) ، R9 او Het ،R8 هو هيدروجين (HYDROGEN) او الكيل (alky1) R9 هو اوكسو (OXO)؛ او R8 و R9 معا يشكلان = CH=CH-N-؛ Alk هوشق هيدروكربون (hydrocarbon radical) مشبع مستقيم او متفرغ له من 1الى 6 ذرات كربون carbon.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05105769 | 2005-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3270B1 true JO3270B1 (ar) | 2018-09-16 |
Family
ID=35445742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2006/0189A JO3270B1 (ar) | 2005-06-28 | 2006-06-25 | مشتقات كوينولين بصفة عوامل مضادة للبكتيريا |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US20100204270A1 (ar) |
| EP (1) | EP1898910B1 (ar) |
| JP (1) | JP5193859B2 (ar) |
| KR (1) | KR101423229B1 (ar) |
| CN (1) | CN101252928B (ar) |
| AP (1) | AP2733A (ar) |
| AR (1) | AR057654A1 (ar) |
| AU (1) | AU2006263884B2 (ar) |
| BR (1) | BRPI0612534B8 (ar) |
| CA (1) | CA2612623C (ar) |
| CY (1) | CY1118515T1 (ar) |
| DK (1) | DK1898910T3 (ar) |
| EA (1) | EA014163B1 (ar) |
| ES (1) | ES2606772T3 (ar) |
| HK (1) | HK1120734A1 (ar) |
| HR (1) | HRP20161704T1 (ar) |
| HU (1) | HUE031268T2 (ar) |
| IL (1) | IL188394A (ar) |
| JO (1) | JO3270B1 (ar) |
| LT (1) | LT1898910T (ar) |
| ME (1) | ME02690B (ar) |
| MX (1) | MX2008000082A (ar) |
| MY (1) | MY151030A (ar) |
| NO (1) | NO341283B1 (ar) |
| NZ (1) | NZ564339A (ar) |
| PL (1) | PL1898910T3 (ar) |
| PT (1) | PT1898910T (ar) |
| RS (1) | RS55408B1 (ar) |
| SG (1) | SG166799A1 (ar) |
| SI (1) | SI1898910T1 (ar) |
| TW (1) | TWI392494B (ar) |
| UA (1) | UA91549C2 (ar) |
| WO (1) | WO2007000436A1 (ar) |
| ZA (1) | ZA200711149B (ar) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9790186B2 (en) | 2009-07-21 | 2017-10-17 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
| DK2841425T3 (en) | 2012-04-27 | 2016-06-27 | Janssen Pharmaceutica Nv | ANTIBACTERIAL QUINOLIN DERIVATIVES |
| JP6153603B2 (ja) | 2012-04-27 | 2017-06-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗菌性キノリン誘導体 |
| CN105037497B (zh) * | 2015-03-27 | 2018-06-26 | 中牧实业股份有限公司 | 一种恩拉霉素的提纯方法 |
| WO2017035288A1 (en) * | 2015-08-27 | 2017-03-02 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| DE19937116A1 (de) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
| SI2301544T1 (sl) * | 2002-07-25 | 2013-01-31 | Janssen Pharmaceutica, N.V. | Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje |
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
-
2006
- 2006-06-25 JO JOP/2006/0189A patent/JO3270B1/ar active
- 2006-06-26 EA EA200800152A patent/EA014163B1/ru unknown
- 2006-06-26 US US11/917,923 patent/US20100204270A1/en not_active Abandoned
- 2006-06-26 SI SI200632126A patent/SI1898910T1/sl unknown
- 2006-06-26 BR BRPI0612534A patent/BRPI0612534B8/pt not_active IP Right Cessation
- 2006-06-26 RS RS20161121A patent/RS55408B1/sr unknown
- 2006-06-26 JP JP2008518812A patent/JP5193859B2/ja not_active Expired - Fee Related
- 2006-06-26 ME MEP-2016-291A patent/ME02690B/me unknown
- 2006-06-26 AP AP2008004300A patent/AP2733A/xx active
- 2006-06-26 DK DK06763891.6T patent/DK1898910T3/en active
- 2006-06-26 PL PL06763891T patent/PL1898910T3/pl unknown
- 2006-06-26 CN CN2006800313527A patent/CN101252928B/zh active Active
- 2006-06-26 PT PT67638916T patent/PT1898910T/pt unknown
- 2006-06-26 AU AU2006263884A patent/AU2006263884B2/en not_active Ceased
- 2006-06-26 CA CA2612623A patent/CA2612623C/en active Active
- 2006-06-26 WO PCT/EP2006/063556 patent/WO2007000436A1/en active Application Filing
- 2006-06-26 UA UAA200714716A patent/UA91549C2/ru unknown
- 2006-06-26 MX MX2008000082A patent/MX2008000082A/es active IP Right Grant
- 2006-06-26 EP EP06763891.6A patent/EP1898910B1/en active Active
- 2006-06-26 ES ES06763891.6T patent/ES2606772T3/es active Active
- 2006-06-26 KR KR1020087002248A patent/KR101423229B1/ko active IP Right Grant
- 2006-06-26 LT LTEP06763891.6T patent/LT1898910T/lt unknown
- 2006-06-26 SG SG201007977-0A patent/SG166799A1/en unknown
- 2006-06-26 NZ NZ564339A patent/NZ564339A/en not_active IP Right Cessation
- 2006-06-26 HU HUE06763891A patent/HUE031268T2/en unknown
- 2006-06-27 AR ARP060102760A patent/AR057654A1/es unknown
- 2006-06-27 MY MYPI20063045 patent/MY151030A/en unknown
- 2006-06-27 TW TW095123051A patent/TWI392494B/zh not_active IP Right Cessation
-
2007
- 2007-12-20 ZA ZA200711149A patent/ZA200711149B/xx unknown
- 2007-12-25 IL IL188394A patent/IL188394A/en active IP Right Grant
-
2008
- 2008-01-25 NO NO20080481A patent/NO341283B1/no not_active IP Right Cessation
- 2008-11-18 HK HK08112595.6A patent/HK1120734A1/xx not_active IP Right Cessation
-
2012
- 2012-08-07 US US13/568,597 patent/US20130030017A1/en not_active Abandoned
-
2016
- 2016-12-13 HR HRP20161704TT patent/HRP20161704T1/hr unknown
- 2016-12-20 CY CY20161101322T patent/CY1118515T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200744594A (en) | Quinoline derivatives as antibacterial agents | |
| TW200744595A (en) | Quinoline derivatives as antibacterial agents | |
| PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
| HK1138262A1 (en) | Novel phosphodiesterase inhibitors | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| JO3322B1 (ar) | مشتقات كوينولين بصفة عوامل مضادة للبكتيريا | |
| JO3270B1 (ar) | مشتقات كوينولين بصفة عوامل مضادة للبكتيريا | |
| CY1113535T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
| MY153291A (en) | Quinoline derivatives as antibacterial agents | |
| WO2005070924A8 (en) | Substituted quinolines and their use as mycobacterial inhibitors | |
| JO2695B1 (ar) | معالجة السل الكامن | |
| TW200738637A (en) | Compounds having activity at NK3 receptor and uses thereof in medicine |